Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 14, Issue 3, Pages 169-186Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrclinonc.2016.162
Keywords
-
Categories
Funding
- Engineering and Physical Sciences Research Council [A/15267, A/16463, A/16464, A/16465, A/16466, A/18097]
- Innovative Medicines Initiative Joint Undertaking [115151]
- European Union
- EPSRC [EP/M020533/1, EP/H046410/1, EP/K020439/1] Funding Source: UKRI
- MRC [MR/N020782/1, MR/J007986/1, G0300648, G0701533, MC_UP_1302/4] Funding Source: UKRI
- Cancer Research UK [11566, 12011, 19908, 10348, 19278, 11562, 10342, 16267, 9993, 18097, 10345, 15267, 16584, 22897, 16463, 10337, 21993, 22746, 16628, 16466, 16464, 17242, 16049, 8971, 11359, 18974, 16465] Funding Source: researchfish
- Cancer Research UK
- Versus Arthritis [20000] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [EP/K020439/1, EP/H046410/1, EP/M020533/1] Funding Source: researchfish
- Medical Research Council [MC_UP_1302/4, MR/J007986/1, MR/N020782/1, G0701533, G0300648] Funding Source: researchfish
- National Institute for Health Research [NIHR-RP-02-12-019, NF-SI-0611-10163, CL-2007-18-015, NF-SI-0515-10045, NF-SI-0513-10019, NF-SI-0512-10162, NF-SI-0509-10143, NIHR/CS/009/009, NF-SI-0515-10067] Funding Source: researchfish
- Wellbeing of Women [RG1705] Funding Source: researchfish
Ask authors/readers for more resources
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available